of patients with early-stage EGFR-mutated lung cancer Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China where Tagrisso reduced the risk of disease recurrence or death by 80%
AstraZeneca s Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient s physician. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
What s Going On With NVCR Stock And VTV Stock Today? benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.
email article
Adding the immune checkpoint inhibitor nivolumab (Opdivo) to neoadjuvant chemotherapy dramatically increased pathologic complete response (pCR) in patients with operable lung cancer, a randomized trial showed.
The pCR rate increased from 2.2% with chemotherapy alone to 24.0% with the addition of nivolumab. The between-group difference increased in an analysis limited to patients who had complete resection. Clearance of circulating tumor (ct) DNA during neoadjuvant therapy increased the likelihood of pCR, reported Patrick M. Forde, MD, of the Johns Hopkins Sidney Kimmel Cancer Center in Baltimore, at the American Association for Cancer Research (AACR) virtual meeting. CheckMate 816 showed a statistically significant improvement in pCR, said Forde. This benefit was consistent across disease stages, histology, TMB (tumor mutational burden) and PD-L1 expression. The study continues to mature for the event-free survival (EFS) primary endpoint.
Share this article
LAS VEGAS, April 12, 2021 /PRNewswire/ The
Cancer Anorexia report provides a detailed view of the Cancer Anorexia market forecasts up to 2030, analysis of treatment landscape, promising emerging therapies, changing market landscape, individual market share of pipeline therapies, Cancer Anorexia market drivers, and market barriers, Cancer Anorexia market size during the study period 2018-30 in the 7MM.
The
Cancer Anorexia Market report is created to uncover authentic opportunities in the Cancer Anorexia market landscape in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France), and Japan), help clients form collaborations and ink deals that give them a competitive advantage and plan strategic moves to yield maximum returns.